Major Movers on April 19; RH, VRTX, IBM, ACTG, MSFT, EFII

Restoration Hardware Holdings Inc.  (NYSE: RH) skyrocketed about 20% by midday trading after the home furnisher, late last evening reported very strong fiscal fourth quarter results and provided upbeat guidance on the fiscal first quarter and full-year. The Company reported earnings of 64 cents a share, while analysts’ consensus estimate was for earnings of 60 cents a share, according to a data compiled by Thomson Reuters. Net revenue surged about 30% to $398.05 million in the fiscal fourth quarter from $305.24 million, in the same quarter of last year. Analysts’ consensus forecast was for revenue of $390.86 million. Same-store-sales soared 26%. For the fiscal first quarter, the Company expects revenue growth 28% to 31%. For the full fiscal year, it expects revenue growth of 19% to 22%.

Continue reading Major Movers on April 19; RH, VRTX, IBM, ACTG, MSFT, EFII

Vertex Pharmaceuticals Shares Soar over VX-661 Mid-Stage Results (VRTX)

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) skyrocketed 52.26% during afterhours trading on Thursday after the company said that mid-stage clinical trial of its unbranded treatment called VX-661 showed significant improvements in lung functions among adults.

Continue reading Vertex Pharmaceuticals Shares Soar over VX-661 Mid-Stage Results (VRTX)

Vertex Pharmaceuticals Shares Surge on Encouraging Clinical Data (VRTX)

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), a biotechnology company engaged in the discovery, development, manufacturing and commercialization of small molecule drugs for the treatment of serious diseases, on Monday, reported that the new cystic fibrosis drug Kalydeco when combined with its experimental treatment for the disease led to substantially improved breathing ability in a mid-stage study.

Continue reading Vertex Pharmaceuticals Shares Surge on Encouraging Clinical Data (VRTX)